Cell News and Research

RSS

BCRI study evaluates the effect of high-doses of vitamin C on inhibition of new blood vessel growth

Bio-Communications Research Institute's recent research study has found that high levels of vitamin C (ascorbate) inhibit the formation of new blood vessel growth to tumors.

27 Feb 2010

Cell Therapeutics files 2009 Annual Report on Form 10-K

Cell Therapeutics, Inc. today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2009. This filing is available for review on CTI's website at www.CellTherapeutics.com, or on the Securities and Exchange Commission's website at www.sec.gov.

27 Feb 2010

Shire receives marketing approval from FDA for VPRIV

Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.

27 Feb 2010

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.

27 Feb 2010

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia.

27 Feb 2010

Gene signature may help identify risk of colon cancer recurrence

A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study by Vanderbilt-Ingram Cancer Center researchers.

26 Feb 2010

Manage Mobility, BEMS partner to sell SMARTHOMECARE and SECURITYSMART applications in the U.S.

Manage Mobility, a Sprint Exclusive Business Solutions Partner, today announced that it has signed an agreement with BEMS, Inc., a regional provider of security systems and life safety technology, to sell its new SMARTHOMECARE™ and SECURITYSMART™ applications to existing enterprise customers in the United States.

26 Feb 2010

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and materials and have been evaluated based on business model, strategies for deploying and scaling up its technologies and the likelihood of success. Each company in the 2010 TR50 has excelled not only at inventing technology but also at using it to transform how we live and work.

26 Feb 2010

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Alexion Pharmaceuticals, Inc., has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the third annual Rare Disease Day, February 28, 2010.

26 Feb 2010

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.

26 Feb 2010

Mutations in MeCP2 cause autism spectrum disorder Rett Syndrome

A paper published online today in Molecular Cell proposes that Methyl CpG binding protein 2 (MeCP2) impacts the entire genome in neurons, rather than acting as a regulator of specific genes. Mutations in MeCP2 cause the autism spectrum disorder Rett Syndrome as well as some cases of neuropsychiatric problems including autism, schizophrenia and learning disabilities.

26 Feb 2010

UCLA School of Nursing selects CytoCore's PadKit Collection Kit for comparative cytology study of cervical cancer

CytoCore Inc., the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, announced today that PadKit® Collection Kit, a transport kit using an intralabial device for the collection of gynecological samples, has been selected by the UCLA School of Nursing as the sample collection system for a comparative cytology study of cervical cancer.

26 Feb 2010

Librede to develop technologies for improving ion channel drug discovery and screening at CNSI incubator

Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.

26 Feb 2010

NIH Director announces seven new scientific programs scheduled to begin during fiscal year 2010

Programs to create a new center for the study of stem cells and to increase capacity to deal with global health issues were among seven scientific initiatives announced today by NIH Director Francis S. Collins, M.D., Ph.D. The seven research programs are supported through the NIH Common Fund, which encourages collaborative research programs across the NIH institutes and centers, or ICs, to accomplish work that no single IC could do alone.

26 Feb 2010

Individuals who naturally lack CCR5 receptor have resistant to HIV

UCLA AIDS Institute researchers successfully removed CCR5 - a cell receptor to which HIV-1 binds for infection but which the human body does not need - from human cells. Individuals who naturally lack the CCR5 receptor have been found to be essentially resistant to HIV.

26 Feb 2010

Hard to Treat Diseases completes cosmetic micro-conglomerate merger

Hard to Treat Diseases (http://www.htdsmedical.com/) - Further to the previously announced cosmetics merger (press release Feb 5, 2010) negotiations with the cosmetic company Melem Secrets, and other business matters the company is pleased to report that it has completed a cosmetic micro-conglomerate merger.

26 Feb 2010

MetLife Foundation Awards for Medical Research in Alzheimer's Disease: Four scientists honored

Complementary approaches to Alzheimer's research were recognized as four scientists received the prestigious MetLife Foundation Awards for Medical Research in Alzheimer's Disease in Washington, D.C.

26 Feb 2010

Comprehensive development strategy yields two potential drugs that block cancer-promoting pathways

A comprehensive drug development strategy that starts with extensive screening of potential targeting agents and then narrows down to a small-molecule prototype has yielded two potential drugs that block cancer-promoting pathways in novel ways, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in two papers published back-to-back online at the Proceedings of the National Academies of Science.

26 Feb 2010

New dietary supplement blocks triggering mechanism causing breast cell mutations

Every 13 minutes a woman loses her battle with breast cancer and in 2009 alone more than 27,000 men died from prostate cancer. These powerful statistics continue to fuel research and new developments. With tens of millions of dollars in financial support from the National Cancer Institute and the U.S. Department of Defense, scientists have identified when estrogen metabolism is out of balance it can start the process leading to breast cell mutations.

26 Feb 2010

Antiretroviral therapy reduces mortality rates in patients co-infected with HIV and TB

Initiating antiretroviral therapy (ART) during tuberculosis therapy significantly reduced mortality rates by 56 percent in a randomized clinical trial of 642 patients co-infected with HIV and tuberculosis. The study, which provides further impetus for the integration of TB and HIV services, lays to rest the controversy on whether co-infected patients should initiate ART during or after TB treatment.

26 Feb 2010

Cell News and Research

BCRI study evaluates the effect of high-doses of vitamin C on inhibition of new blood vessel growth

Cell Therapeutics files 2009 Annual Report on Form 10-K

Shire receives marketing approval from FDA for VPRIV

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Gene signature may help identify risk of colon cancer recurrence

Manage Mobility, BEMS partner to sell SMARTHOMECARE and SECURITYSMART applications in the U.S.

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Mutations in MeCP2 cause autism spectrum disorder Rett Syndrome

UCLA School of Nursing selects CytoCore's PadKit Collection Kit for comparative cytology study of cervical cancer

Librede to develop technologies for improving ion channel drug discovery and screening at CNSI incubator

NIH Director announces seven new scientific programs scheduled to begin during fiscal year 2010

Individuals who naturally lack CCR5 receptor have resistant to HIV

Hard to Treat Diseases completes cosmetic micro-conglomerate merger

MetLife Foundation Awards for Medical Research in Alzheimer's Disease: Four scientists honored

Comprehensive development strategy yields two potential drugs that block cancer-promoting pathways

New dietary supplement blocks triggering mechanism causing breast cell mutations

Antiretroviral therapy reduces mortality rates in patients co-infected with HIV and TB

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News